Carbamazepine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
US
  • Trigeminal Neuralgia Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.
Product first approved 1968FDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Epilepsy
NCT00236717 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1997-09 – 2000-11 · Epilepsy, Seizures
What this study did
Other / comorbidity
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00266630 · Eli Lilly and Company
2005-11 – 2009-05 · Manic or Mixed Episode Associated With Bipolar I Disorder
What this study did
NCT00150553 · Validus Pharmaceuticals
2005-01 – 2005-10 · Bipolar Disorder
What this study did
NCT00150605 · Validus Pharmaceuticals
2005-02 – 2005-10 · Bipolar Disorder
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00913107 · University of Malaya
2007-09 – 2008-06 · Trigeminal Neuralgia
What this study did
Phase 2 (9)
Epilepsy
NCT00894010 · The Epilepsy Study Consortium
2009-05 – 2011-06 · Photosensitive Epilepsy
What this study did
NCT00004758 · National Center for Research Resources (NCRR)
started 1993-11 · Spasms, Infantile, Epilepsy
What this study did
Other / comorbidity
NCT06316362 · Alexandria University
2022-01-01 – 2023-02-28 · Acute Poisoning
What this study did
NCT01379469 · Washington University School of Medicine
2012-01 – 2017-02 · Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
What this study did
NCT01581918 · Faculdade de Medicina do ABC
2011-12 – 2012-03 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT00294892 · Radboud University Medical Center
2006-02 – 2010-06 · HIV Infections
What this study did
NCT00000242 · Medical University of South Carolina
1992-10-01 – 1997-01-25 · Cocaine-Related Disorders, Substance-Related Disorders
What this study did
NCT00000217 · University of Kansas
1990-09 – 1996-10 · Cocaine-Related Disorders, Substance-Related Disorders
What this study did
NCT00000191 · University of Pennsylvania
1991-01 – 1994-02 · Cocaine-Related Disorders
What this study did
Phase 1 (54)
Epilepsy
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT02284854 · Bial - Portela C S.A.
2009-07 – 2009-11 · Epilepsy
What this study did
Other / comorbidity
NCT07939594 · ViiV Healthcare
2026-11-16 – 2027-03-12 · HIV Infections
What this study did
NCT07570082 · Crinetics Pharmaceuticals Inc.
2026-05-28 – 2026-07-30 · Healthy Volunteers
What this study did
NCT07449390 · Acesion Pharma
2026-04-01 – 2026-05-16 · Healthy Participants
What this study did
NCT04923659 · University Health Network, Toronto
2021-05-25 – 2026-05 · Low Intensity Focussed Ultrasound
What this study did
NCT07279233 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
2025-12-15 – 2026-02-27 · Healthy, Volunteer
What this study did
NCT07100964 · Boehringer Ingelheim
2025-08-11 – 2025-10-01 · Healthy
What this study did
NCT06965881 · GRIN Therapeutics, Inc.
2025-05-08 – 2025-07-08 · Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders
What this study did
NCT06672900 · Aligos Therapeutics
2025-01-09 – 2025-07-07 · Healthy Volunteer
What this study did
NCT06897683 · Pfizer
2025-03-21 – 2025-06-12 · Healthy Adults
What this study did
NCT06847464 · Enanta Pharmaceuticals, Inc
2025-01-27 – 2025-06-01 · RSV Infection, Drug Drug Interaction (DDI)
What this study did
NCT06914869 · X4 Pharmaceuticals
2025-02-18 – 2025-05-19 · Healthy Participants
What this study did
NCT06633419 · Merck Sharp & Dohme LLC
2024-12-18 – 2025-05-13 · Healthy
What this study did
NCT06596668 · Merck Sharp & Dohme LLC
2024-10-02 – 2025-03-11 · Healthy
What this study did
NCT06751017 · Shionogi
2024-12-17 – 2025-02-24 · COVID-19
What this study did
NCT06671405 · AstraZeneca
2024-09-25 – 2025-02-17 · Dyslipidaemia
What this study did
NCT06370728 · Eli Lilly and Company
2024-05-06 – 2024-07-23 · Healthy
What this study did
NCT06345794 · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
2024-04-03 – 2024-06-18 · Healthy
What this study did
NCT06348888 · Bayer
2024-04-10 – 2024-06-12 · Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
What this study did
NCT06173596 · Alexion Pharmaceuticals, Inc.
2024-01-10 – 2024-05-16 · Healthy
What this study did
NCT06071442 · Alexion Pharmaceuticals, Inc.
2024-01-17 – 2024-04-12 · Healthy Participants
What this study did
NCT06028464 · Boehringer Ingelheim
2023-09-11 – 2023-12-08 · Healthy
What this study did
NCT06005688 · Pfizer
2023-08-18 – 2023-11-21 · Healthy Participants
What this study did
NCT05932303 · Bristol-Myers Squibb
2023-07-12 – 2023-10-23 · Healthy Participants
What this study did
NCT05994807 · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
2023-08-08 – 2023-09-20 · Healthy Volunteers
What this study did
NCT05860933 · Eli Lilly and Company
2023-05-08 – 2023-08-28 · Healthy
What this study did
NCT05824143 · Cerevel Therapeutics, LLC
2023-04-17 – 2023-07-07 · Healthy Participants
What this study did
NCT05552196 · Janssen Pharmaceutica N.V., Belgium
2022-10-18 – 2023-03-29 · Healthy
What this study did
NCT05581823 · Cerevel Therapeutics, LLC
2022-10-19 – 2023-02-02 · Parkinson Disease
What this study did
NCT05594602 · Enanta Pharmaceuticals, Inc
2022-10-06 – 2022-12-30 · COVID-19
What this study did
NCT07542847 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-09-19 – 2022-12-11 · Healthy Volunteers
What this study did
NCT05418582 · Dizal Pharmaceuticals
2022-01-25 – 2022-12-08 · Healthy Subjects
What this study did
NCT05486949 · Dizal Pharmaceuticals
2022-07-27 – 2022-10-11 · Healthy Subjects
What this study did
NCT05248945 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2022-01-13 – 2022-07-18 · Healthy
What this study did
NCT04330248 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2020-03-31 – 2022-06-14 · Healthy
What this study did
NCT05213481 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2021-12-15 – 2022-05-06 · Healthy
What this study did
NCT05205447 · Eli Lilly and Company
2022-01-05 – 2022-04-12 · Healthy
What this study did
NCT04840888 · Eli Lilly and Company
2021-04-26 – 2022-04-12 · Healthy
What this study did
NCT05028608 · Bayer
2021-09-06 – 2022-01-20 · Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
What this study did
NCT04783753 · Enanta Pharmaceuticals, Inc
2020-11-05 – 2021-07-09 · Hepatitis B
What this study did
NCT02132897 · Center for Clinical Pharmacology Research Bdbeq S.A.
2014-05 – 2014-06 · Bio-equivalence Study, Fed Conditions
What this study did
NCT01967771 · ViiV Healthcare
2013-10 – 2014-01 · Infection, Human Immunodeficiency Virus
What this study did
NCT01530022 · UCB Pharma
2012-05 – 2014-01 · Healthy
What this study did
Phase 4 (25)
Epilepsy
NCT03307863 · University of Sao Paulo
2017-11-01 – 2028-11-30 · Contraception, Drug Interactions
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT05748236 · Dhaka Medical College
2022-11-01 – 2023-10 · Focal Epilepsy
What this study did
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did
NCT04610879 · King's College London
2019-08-02 – 2020-09-23 · Rolandic Epilepsy
What this study did
NCT04967326 · Gia Dinh People Hospital
2016-01-01 – 2018-12-31 · Epilepsy
What this study did
NCT02912364 · Stanford University
2016-07 – 2018-04-20 · Epilepsy
What this study did
NCT02705768 · All India Institute of Medical Sciences, Bhubaneswar
2016-04 – 2017-03 · Seizures, Focal
What this study did
NCT00438451 · Johannes Gutenberg University Mainz
2007-01 – 2011-08 · Focal Epilepsy
What this study did
Other / comorbidity
NCT02623504 · Validus Pharmaceuticals
2016-10-24 – 2018-11-01 · Bipolar Disorder
What this study did
NCT02214615 · VA Connecticut Healthcare System
2014-04 – 2016-07 · Erythromelalgia
What this study did
NCT02870283 · Federal University of Rio Grande do Sul
2010-05 – 2015-09 · Bipolar Disorder
What this study did
NCT00976794 · University of Sao Paulo
2009-01 – 2012-06 · Bipolar I Disorder
What this study did
NCT01089855 · Novartis
2009-12 – 2010-07 · Neuropathic Pain
What this study did
NCT00203567 · Tuscaloosa Research & Education Advancement Corporation
2005-08 – 2008-05 · Bipolar Depression
What this study did
NCT00325286 · Creighton University
2006-05 – 2008-03 · Bipolar Disorder
What this study did
NCT00350857 · Validus Pharmaceuticals
2006-07 – 2007-10 · Bipolar I Disorder
What this study did
NCT00181870 · Massachusetts General Hospital
2005-07 – 2007-08 · Bipolar Disorder, Mania
What this study did
NCT00260247 · Odense University Hospital
2005-04 – 2006-10 · Metabolic Clearance Rate
What this study did
NCT00190892 · Eli Lilly and Company
2004-09 – 2006-06 · Bipolar Disorder
What this study did
NCT00000218 · National Institute on Drug Abuse (NIDA)
est. completion 2005-06 · Cocaine-Related Disorders, Substance-Related Disorders
What this study did
NCT00153296 · Centre of Chinese Medicine, Georgia
2004-08 – 2005-04 · Bronchial Asthma
What this study did
NCT00006395 · National Institutes of Health Clinical Center (CC)
2000-10 – 2001-04 · Healthy
What this study did
NCT00000441 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
est. completion 2000-12 · Alcoholism
What this study did
NCT00207428 · Centre of Chinese Medicine, Georgia
1999-08 – 2000-04 · Bronchial Asthma
What this study did
Early phase / not applicable (7)
Epilepsy
NCT00208520 · Dutch Epilepsy Clinics Foundation
2003-07 – 2007-06 · Adults With Tonic Clonic Seizures and/or Partial Seizures
What this study did
NCT00381537 · Institute of Child Health
— · Epilepsy
What this study did
Other / comorbidity
NCT07252453 · Abbasi Shaheed Hospital
2025-05-20 – 2025-12-01 · Trigeminal Neuralgia
What this study did
NCT06357260 · Postgraduate Institute of Dental Sciences Rohtak
2024-04-01 – 2025-03 · Trigeminal Neuralgia
What this study did
NCT03580317 · Zhejiang Chinese Medical University
2018-07-12 – 2021-01-31 · Trigeminal Neuralgia
What this study did
NCT00621751 · Wake Forest University Health Sciences
2008-02 – 2013-10 · Traumatic Brain Injury
What this study did
NCT00952432 · Taipei Medical University WanFang Hospital
2009-05 – 2011-05 · Carpal Tunnel Syndrome, Multiple Excitability Test
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Epilepsy
NCT01465997 · UCB BIOSCIENCES GmbH
2012-05 – 2017-01 · Epilepsy, Monotherapy
What this study did
NCT01954121 · UCB Pharma SA
2013-09 – 2015-09 · Epilepsy, Partial Seizures
What this study did
NCT00542802 · Scienze Neurologiche Ospedaliere
2007-09 – 2009-06 · Epileptic Seizures, Stroke
What this study did
Phase 2 (1)
Other / comorbidity
NCT07304453 · Karbala University
2024-01-07 – 2024-09-30 · Trigeminal Neuralgia, Neuropathic Pain
What this study did
Phase 4 (6)
Epilepsy
NCT00807989 · Yonsei University
2008-03 – 2012-05 · Epilepsy
What this study did
NCT01127256 · Eisai Korea Inc.
2006-05-31 – 2009-07-31 · Epilepsy
What this study did
NCT00896987 · Korean Epilepsy Society
2006-05 – 2008-12 · Epilepsy
What this study did
Other / comorbidity
NCT06849219 · Jinnah Postgraduate Medical Centre
2024-09-21 – 2025-03-21 · Trigeminal Neuralgia
What this study did
NCT04996199 · Postgraduate Institute of Dental Sciences Rohtak
2021-09-18 – 2022-01-31 · Trigeminal Neuralgia
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT07750730 · Beijing Hospital of Traditional Chinese Medicine
2026-08-31 – 2027-08-31 · Trigeminal Neuralgia (TN)
What this study did
NCT07907406 · Lahore General Hospital
2026-01-01 – 2026-06-30 · Guillain-Barré Syndrome, Neuropathic Pain
What this study did
NCT01382017 · University of Kiel
2011-06 – 2012-08 · Healthy Male Volunteers
What this study did
Appears in other studies (11)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (9)
Other / comorbidity
NCT07395024 · Astellas Pharma Global Development, Inc.
2026-02-03 – 2027-05-02 · Healthy Volunteer
What this study did
NCT07781631 · Boehringer Ingelheim
2026-09-10 – 2026-12-20 · Healthy
What this study did
NCT07446400 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-03-31 – 2026-11-07 · Healthy Volunteers
What this study did
NCT07775261 · H. Lundbeck A/S
2026-08-27 – 2026-11-06 · Healthy Participants
What this study did
NCT07884734 · GRIN Therapeutics, Inc.
2026-06-08 – 2026-10-31 · Healthy Adult Participants
What this study did
NCT04962230 · Pfizer
2021-07-15 – 2021-10-09 · Healthy Participant
What this study did
NCT04784000 · Atea Pharmaceuticals, Inc.
2021-03-01 – 2021-04-10 · Healthy Volunteer Study
What this study did
NCT01629368 · Hoffmann-La Roche
2012-06 – 2012-09 · Healthy Volunteer
What this study did
NCT00892125 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-09 – 2007-03 · Schizophrenia, Bipolar Disorder
What this study did
Phase 4 (1)
Other / comorbidity
NCT03161509 · Rambam Health Care Campus
2017-07-01 – 2019-01-01 · Bariatric Surgery Candidate
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07673549 · Beijing Tiantan Hospital
2026-08-31 – 2027-12-31 · Idiopathic Trigeminal Neuralgia
What this study did

Competitive landscape

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Carbamazepine: this drugApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Carbamazepine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 1HIV InfectionsNot yet recruiting
Est. primary completion 2027-03-12 · NCT07939594 · CT.gov ↗
What to watch

See the full readout calendar ↗